Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
作者信息
Breteler M M
出版信息
BMJ. 1998 Apr 18;316(7139):1182-3. doi: 10.1136/bmj.316.7139.1182.
Abstract
摘要
相似文献
1
Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
BMJ. 1998 Apr 18;316(7139):1182-3. doi: 10.1136/bmj.316.7139.1182.
2
Selegiline and excess mortality.
Clin Neuropharmacol. 1997 Dec;20(6):542. doi: 10.1097/00002826-199712000-00006.
3
[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Rev Neurol (Paris). 1996 Feb;152(2):103-5.
4
Selegiline in Parkinson's disease.
BMJ. 1995 Dec 16;311(7020):1583-4. doi: 10.1136/bmj.311.7020.1583.
5
6
7
Deprenyl in Parkinson's disease.
Ann Neurol. 1996 Aug;40(2):268-9. doi: 10.1002/ana.410400229.
8
Deprenyl and levodopa and Parkinson's disease progression.
Ann Neurol. 1996 Aug;40(2):267-8. doi: 10.1002/ana.410400228.
9
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):280; author reply 281-2.
10
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):280-2.
引用本文的文献
1
Monoamine oxidase B inhibitors for early Parkinson's disease.
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD004898. doi: 10.1002/14651858.CD004898.pub2.
2
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Drug Saf. 1998 Jul;19(1):11-22. doi: 10.2165/00002018-199819010-00002.
本文引用的文献
1
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
BMJ. 1998 Apr 18;316(7139):1191-6. doi: 10.1136/bmj.316.7139.1191.
2
Unexpected findings of study of selegiline have not been treated with caution its authors advised.
BMJ. 1997 Aug 9;315(7104):370.
3
Selegiline and mortality in Parkinson's disease.
Ann Neurol. 1996 Dec;40(6):841-5. doi: 10.1002/ana.410400605.
4
Prevalence of Parkinson's disease in the elderly: the Rotterdam Study.
Neurology. 1995 Dec;45(12):2143-6. doi: 10.1212/wnl.45.12.2143.
5
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
BMJ. 1996 Mar 16;312(7032):702-3; author reply 704-5.
6
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
BMJ. 1995 Dec 16;311(7020):1602-7. doi: 10.1136/bmj.311.7020.1602.
7
Effect of deprenyl on the progression of disability in early Parkinson's disease.
N Engl J Med. 1989 Nov 16;321(20):1364-71. doi: 10.1056/NEJM198911163212004.
Zotero 插件